Kallidinogenase normalizes retinal vasopermeability in streptozotocin-induced diabetic rats: Potential roles of vascular endothelial growth factor and nitric oxide

European Journal of Pharmacology

Volumn 606, Issue 1-3, 2009, Pages 187-190

  Kato, Noriaki ^a   Hou, Yunlong ^b   Lu, Zhenhui ^a   Lu, Chunmei ^b   Nagano, Hiroshi ^a   Suzuma, Kiyoshi ^c   Takagi, Hitoshi ^d   Matsumoto, Yukiharu ^a  

^a SANWA KAGAKU KENKYUSHO CO LTD   (Japan)

^b HARBIN MEDICAL UNIVERSITY   (China)

^c SHIZUOKA GENERAL HOSPITAL   (Japan)

^d ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Kallidinogenase; Nitric oxide; Vascular endothelial growth factor; Vascular permeability

Indexed keywords

DEXTRAN; FLUORESCEIN ISOTHIOCYANATE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; KALLIKREIN; NITRATE; NITRIC OXIDE; NITRITE; STREPTOZOCIN; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL PERMEABILITY; BODY WEIGHT; CONTROLLED STUDY; DIABETIC RETINOPATHY; DRUG EFFECT; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; GLUCOSE BLOOD LEVEL; KALLIKREIN KININ SYSTEM; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RETINA BLOOD VESSEL; STREPTOZOCIN DIABETES; TREATMENT DURATION;

ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; CAPILLARY PERMEABILITY; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC RETINOPATHY; HEMOGLOBIN A, GLYCOSYLATED; KALLIKREINS; MALE; NITRIC OXIDE; RATS; RATS, SPRAGUE-DAWLEY; RETINA; STREPTOZOCIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 61349114198     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.01.027     Document Type: Article

References (33)

1. Chaturvedi N., Sjolie A.-K., Stephenson J.M., Abrahamian H., Keipes M., Castellarin A., Rogulja-Pepeonik Z., Fuller J.H., and The EUCLID Study Group. Effect of lisinopril on progression of retinopathy in normotensive people with type I diabetes. Lancet 351 (1998) 23-31
2. Chen R., Iwai M., Wu L., Suzuki J., Min L.-J., Shiuchi T., Sugaya T., Liu H.-W., Cui T.-X., and Horiuchi M. Important role of nitric oxide in the effect of angiotensin-converting enzyme inhibitor imidapril on vascular injury. Hypertension 42 (2003) 542-547
3. Cunningham Jr. E.T., Adamis A.P., Altaweel M., Aiello L.P., Bressler N.M., D, Amico D.J., Goldbaum M., Guyer D.R., Katz B., Patel M., Schwartz S.D., and Macugen Diabetic Retinopathy Study Group. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 112 (2005) 1747-1757
4. Faghihi H., Roohipoor R., Mohammadi S.F., Hojat-Jalali K., Mirshahi A., Lashay A., Piri N., and Faghihi S.H. Intravitreal bevacizumab versus combined bevacizumab-triamcinolone versus macular laser photocoagulation in diabetic macular edema. Eur. J. Ophthalmol. 18 (2008) 941-948
5. Franken A.A.M., Derkx F.H.M., Schalekamp M.A.D.H., Man in t', Veld A.J., Hop W.C.J., van Rens E.H., and de Jong P.T.V.M. Association of high plasma prorenin with diabetic retinopathy. J. Hypertens. 6 suppl 4 (1988) S461-S463
6. Funatsu H., Yamashita H., Ikeda T., Nakanishi Y., Kitano S., and Hori S. Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with diabetic macular edema and other retinal disorders. Am. J. Ophthalmol. 133 (2002) 537-543
7. Funatsu H., Yamashita H., Nakanishi Y., and Hori S. Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with proliferative diabetic retinopathy. Br. J. Ophthalmol. 86 (2002) 311-315
8. Funatsu H., Yamashita H., Nakamura S., Mimura T., Eguchi S., Noma H., and Hori S. Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology 113 (2006) 294-301
9. Ghiso N., Rohan R.M., Amano S., Garland R., and Adamis A.P. Suppression of hypoxia-associated vascular endothelial growth factor gene expression by nitric oxide via cGMP. Invest. Ophthalmol. Vis. Sci. 40 (1999) 1033-1039
10. Handa H., Sakurama S., Nakagawa S., Yasukouchi T., Sakamoto W., and Izumi H. Glandular kallikrein, rennin and angiotensin converting enzyme of diabetic and hypertensive rats. Adv. Exp. Med. Biol. 247B (1989) 443-448
11. Hatcher H.C., Ma J.-X., Chao J., Chao L., and Ottlecz A. Kallikrein-binding protein levels are reduced in the retinas of streptozotocin-induced diabetic rats. Invest. Ophthalmol. Vis. Sci. 38 (1997) 658-664
12. Jaffa A.A., Miller D.H., Bailey G.S., Chao J., Margolius H.S., and Mayfield R.K. Abnormal regulation of renal kallikrein in experimental diabetes. Effects of insulin on prokallikrein synthesis and activation. J. Clin. Invest. 80 (1987) 1651-1659
13. Koide A., Zeitlin I.J., and Parratt J.R. Kinin formation in ischaemic heart and aorta of anaesthetized rats. J. Physiol. 467 (1993) 125P (Lond)
14. Kroll J., and Waltenberger J. VEGF-A induces expression of eNOS and iNOS in endothelial cells via VEGF receptor-2 (KDR). Biochem. Biophys. Res. Commun. 252 (1998) 743-746
15. Ma J.-X., King L.P., Yang Z., Crouch R.K., Chao L., and Chao J. Kallistatin in human ocular tissues: reduced levels in vitreous fluids from patients with diabetic retinopathy. Curr. Eye Res. 15 (1996) 1117-1123
16. Nagano H., Pan Z.W., Chen Q.W., Jomori T., Oku H., Ikeda T., Saito Y., and Tano Y. Effects of kallidinogenase on ischemic changes induced by repeated intravitreal injections of endothelin-1 in rabbit retina. Curr. Eye Res. 32 (2007) 113-122
17. Nguyen Q.D., Tatlipinar S., Shah S.M., Haller J.A., Quinlan E., Sung J., Zimmer-Galler I., Do D.V., and Campochiaro P.A. Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. Am. J. Ophthalmol. 142 (2006) 961-969
18. Pinna A., Emanueli C., Dore S., Salvo M., Madeddu P., and Carta F. Levels of human tissue kallikrein in the vitreous fluid of patients with severe proliferative diabetic retinopathy. Ophthalmologica. 218 (2004) 260-263
19. Rothschild A.M., Melo V.L., Reis M.L., Foss M.C., and Gallo Jr. L. Kininogen and prekallikrein increases in the blood of streptozotocin-diabetic rats are normalized by insulin in vivo and in vitro. Naunyn-Schmiedeberg's Arch. Pharmacol. 360 (1999) 217-220
20. Schmaier A.H. The plasma kallikrein-kinin system counterbalances the rennin-angiotensin system. J. Clin. Invest. 109 (2002) 1007-1009
21. Sharma J.N., Abbas S.A., Yusof A.P.M., and Shah R.P. Evaluation of tissue kallikrein activity on survival time after acute coronary artery ligation in hypertensive rats. Int. Immunopharmacol. 3 (2003) 329-334
22. Takagi H. Molecular mechanisms of retinal neovascularization in diabetic retinopathy. Intern. Med. 42 (2003) 299-301
23. Tamura H., Miyamoto K., Kiryu J., Miyahara S., Katsuta H., Hirose F., Musashi K., and Yoshimura N. Intravitreal injection of corticosteroid attenuates leukostasis and vascular leakage in experimental diabetic retina. Invest. Ophthalmol. Vis. Sci. 46 (2005) 1440-1444
24. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS38. B.M.J. 317 (1998) 703-713
25. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular complications in type 2 diabetes: UKPDS 39. B.M.J. 317 (1998) 713-720
26. Vegh A., Szekeres L., and Parratt J.R. Local intracoronary infusions of bradykinin profoundly reduce the severity of ischaemia-induced arrhythmias in anaesthetized dogs. Br. J. Pharmacol. 104 (1991) 294-295
27. Wall T.M., Sheehy R., and Hartman J.C. Role of bradykinin in myocardial preconditioning. J. Pharmacol. Exp. Ther. 270 (1994) 681-689
28. Watanabe D., Suzuma K., Suzuma I., Ohashi H., Ojima T., Kurimoto M., Murakami T., Kimura T., and Takagi H. Vitreous levels of angiopoietin 2 and vascular endothelial growth factor in patients with proliferative diabetic retinopathy. Am. J. Ophthalmol. 139 (2005) 476-481
29. Witmer A.N., Vrensen G.F.J.M., Van Noorden C.J.F., and Schlingemann R.O. Vascular endothelial growth factors and angiogenesis in eye disease. Prog. Retin. Eye Res. 22 (2003) 1-29
30. Yamaguchi T., Nagano H., Yamaguchi M., Suzuki T., Saito Y., and Tano Y. The effects of kallidinogenase on choroidal blood flow in a hypertensive rabbit model. Curr. Eye Res. 18 (1999) 417-422
31. Yamauchi T., Kashii S., Yasuyoshi H., Zhang S., Honda Y., and Akaike A. Mitochondrial ATP-sensitive potassium channel: a novel site for neuroprotection. Invest. Ophthalmol. Vis. Sci. 44 (2003) 2750-2756
32. Yoshida H., Zhang J.J., Chao L., and Chao J. Kallikrein gene delivery attenuates myocardial infarction and apoptosis after myocardial ischemia and reperfusion. Hypertension 35 (2000) 25-31
33. Ziche M., Morbidelli L., Choudhuri R., Zhang H.-T., Donnini S., Granger H.J., and Bicknell R. Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. J. Clin. Invest. 99 (1997) 2625-2634